The latest dive into Medicaid and Medicare prescription drug data shows that the federal health care programs spent more on the Harvoni hepatitis C treatment last year than any other medicine.
Medicare Part D spent slightly more than $7 billion on the Gilead Sciences product, while Medicaid coughed up nearly $2.2 billion for the drug, according to data released today by the Centers for Medicare and Medicaid Services.
The agency released its latest dashboard, an interactive tool that chose a few dozen drugs for which spending or unit costs rose by notable amounts, as well as those brand and generic medicines that contributed to large program spending overall.
